Riociguat rEplacing PDE-5i Therapy evaLuated Against Continued PDE-5i thErapy

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 225 participants.

Also called NCT02891850

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 225 participants (enrolled count) (from the registry)
Sponsor
  • Bayer Registry lists this organization as the lead sponsor
Registry
  • NCT NCT02891850
  • EudraCT 2016-001067-36
Other papers using this trial's data
  • Switching to riociguat versus maintenance therapy with phosphodiesterase-5 inhibitors in patients with pulmonary arterial hypertension (REPLACE): a multicentre, open-label, randomised controlled trial The Lancet. Respiratory medicine, 2021-06 DOI, PubMed 33773120

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Austria, Belgium, Brazil, Canada, Czechia, Denmark, France, Germany, Greece, Italy, Japan, Mexico, Netherlands, Poland, Portugal, South Korea, Spain, Taiwan, Türkiye, United Kingdom (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT02891850. Randomized; no masking; primary purpose treatment. Start 2017-01-11 (actual); primary completion 2020-01-29 (actual). Results posted on 2021-01-22.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Riociguat rEplacing PDE-5i Therapy evaLuated Against Continued PDE-5i thErapy
Acronym
REPLACE
Condition
Pulmonary Arterial Hypertension
Intervention (Drug)
Riociguat (Adempas, BAY63-2521)
Intervention (Drug)
Sildenafil
Intervention (Drug)
Tadalafil
Lead sponsor
Bayer (class: industry)

Record details

Record id
cardio:ct-nct02891850
Content hash
34be75d09e1890137e21ab9cb2f0c69da097f13ce335ebbb3946d48b7ea80fbf